{"schema_version":"bookimed.page-context.v1","id":"doctor-susheel-kodali","url":"https://hub.bookimed.com/heart-surgery/doctor-susheel-kodali/","json_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/doctor-susheel-kodali.json","index_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/index.json","full_dataset_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/content.json","content_revision":"source-driven-rankings-20261008","date_modified":"2026-10-08","language":"en","kind":"doctor-profile","title":"Susheel K. Kodali: transcatheter tricuspid valve treatment","summary":"Susheel Kodali is an NYU Langone interventional cardiologist specialising in transcatheter valve therapies. His trial work is relevant to severe tricuspid leakage, where symptom benefit must be weighed against bleeding and pacemaker risks.","research_credit":{"name":"Yevhenii Kozlov","role":"Co-Founder of Bookimed","url":"https://us-uk.bookimed.com/ceo/kozlov/","contribution":"Research personally prepared and reviewed","assistance":"AI tools assisted source research."},"editorial_scope":"Source-based patient information; an individual treatment plan requires clinical review.","research_method":"How this guide is researched and compared Research project led by Yevhenii Kozlov . We link clinical guidance, primary studies and named hospital or offer sources beside the relevant statements. Comparisons distinguish individual operators from programme results and preserve the study population, follow-up and limitations. Prices are dated examples with their stated scope. Research and editorial preparation are separate from clinical review; no named clinician has medically reviewed this edition. Bookimed provides care coordination. Partner and reference programmes are identified from their sources; paid ordering is not used in our published-cohort comparison. Read the editorial policy .","key_takeaways":[{"label":"Current NYU appointment","text":"NYU announced his move in August 2026; earlier Columbia affiliations belong to his research history.","sources":["SP11","SP12"]},{"label":"Patient-centred benefit","text":"The 400-patient TRISCEND II trial favoured replacement plus medical therapy at one year, principally through symptoms and quality of life.","sources":["SP20"]},{"label":"Material trade-offs","text":"Severe bleeding occurred in 15.4% versus 5.3%, and new pacemakers in 17.4% versus 2.3%, with replacement versus medical therapy.","sources":["SP20"]}],"benefits":[{"text":"For the selected patients studied in TRISCEND II, catheter tricuspid replacement improved symptoms and quality of life over medical therapy alone at one year.","sources":["SP20"]}],"limitations":[{"text":"The trial evaluated one replacement system in selected patients. It does not establish a survival advantage or compare replacement with tricuspid repair or open surgery; its outcomes are not Kodali’s personal rate.","sources":["SP11","SP12","SP20"]}],"sections":[{"id":"benefit-balance","title":"Benefits and limitations","text":"Benefits and limitations Potential advantages For the selected patients studied in TRISCEND II, catheter tricuspid replacement improved symptoms and quality of life over medical therapy alone at one year. Sources: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. Trade-offs and limits The trial evaluated one replacement system in selected patients. It does not establish a survival advantage or compare replacement with tricuspid repair or open surgery; its outcomes are not Kodali’s personal rate. Sources: Susheel K. Kodali, MD — physician profile · NYU welcomes Susheel Kodali to lead interventional cardiology · Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","links":[{"label":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","url":"https://pubmed.ncbi.nlm.nih.gov/39475399/"},{"label":"Susheel K. Kodali, MD — physician profile","url":"https://nyulangone.org/doctors/1659455335/susheel-k-kodali"},{"label":"NYU welcomes Susheel Kodali to lead interventional cardiology","url":"https://nyulangone.org/news/nyu-langone-names-sunil-rao-md-director-leon-h-charney-division-cardiology-and-welcomes-susheel-kodali-md-lead-interventional-cardiology"},{"label":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","url":"https://pubmed.ncbi.nlm.nih.gov/39475399/"}]},{"id":"research","title":"Procedure-specific research","text":"Procedure-specific research Replacement: symptoms, function and procedure risks In the 400-patient TRISCEND II randomized trial, replacement plus medical therapy improved the one-year composite outcome, mainly through symptoms and quality of life. Severe bleeding and new pacemakers were more frequent with replacement. How to interpret this: Device-specific, selected-patient, multicentre evidence. It does not establish a survival advantage or Kodali-specific success rate, and is not a comparison of replacement with tricuspid repair or surgery. Sources: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","links":[{"label":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","url":"https://pubmed.ncbi.nlm.nih.gov/39475399/"}]},{"id":"team","title":"Clinical programme","text":"Clinical programme NYU Langone → New York, United States NYU’s HCM programme combines medical treatment, imaging and surgery. Swistel’s work addresses elongated leaflets and papillary attachments; Scheinerman is named in the hospital’s first reported robotic trans-mitral myectomy. The valve service also includes Kodali’s transcatheter expertise. Sources: NYU Langone · HCM programme · NYU HCM programme · Resect–plicate–release · 77-patient study (2015) · NYU first robotic myectomy clinical case · NYU Langone · Daniel Swistel · Susheel K. Kodali, MD — physician profile · NYU welcomes Susheel Kodali to lead interventional cardiology · Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. Explore the programme and other specialists →","links":[{"label":"NYU Langone →","url":"https://hub.bookimed.com/heart-surgery/clinic-nyu-langone/"},{"label":"NYU Langone · HCM programme","url":"https://nyulangone.org/care-services/hypertrophic-cardiomyopathy-program"},{"label":"NYU HCM programme","url":"https://nyulangone.org/care-services/hypertrophic-cardiomyopathy-program"},{"label":"Resect–plicate–release · 77-patient study (2015)","url":"https://pubmed.ncbi.nlm.nih.gov/26272699/"},{"label":"NYU first robotic myectomy clinical case","url":"https://physicianfocus.nyulangone.org/nyu-langones-first-robotic-septal-myectomy-for-obstructive-hcm/"},{"label":"NYU Langone · Daniel Swistel","url":"https://nyulangone.org/doctors/1083603690/daniel-g-swistel"},{"label":"Susheel K. Kodali, MD — physician profile","url":"https://nyulangone.org/doctors/1659455335/susheel-k-kodali"},{"label":"NYU welcomes Susheel Kodali to lead interventional cardiology","url":"https://nyulangone.org/news/nyu-langone-names-sunil-rao-md-director-leon-h-charney-division-cardiology-and-welcomes-susheel-kodali-md-lead-interventional-cardiology"},{"label":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","url":"https://pubmed.ncbi.nlm.nih.gov/39475399/"},{"label":"Explore the programme and other specialists →","url":"https://hub.bookimed.com/heart-surgery/clinic-nyu-langone/"}]}],"introduction":"Heart surgery guide / Susheel K. Kodali Susheel K. Kodali · Decision guide Susheel K. Kodali: transcatheter tricuspid valve treatment Tricuspid catheter treatment with symptom and risk data · New York, United States Research by Yevhenii Kozlov · Co-Founder of Bookimed Updated 8 October 2026 Sources linked throughout At a glance Susheel Kodali is an NYU Langone interventional cardiologist specialising in transcatheter valve therapies. His trial work is relevant to severe tricuspid leakage, where symptom benefit must be weighed against bleeding and pacemaker risks. Current NYU appointment NYU announced his move in August 2026; earlier Columbia affiliations belong to his research history. Sources: Susheel K. Kodali, MD — physician profile · NYU welcomes Susheel Kodali to lead interventional cardiology Patient-centred benefit The 400-patient TRISCEND II trial favoured replacement plus medical therapy at one year, principally through symptoms and quality of life. Sources: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. Material trade-offs Severe bleeding occurred in 15.4% versus 5.3%, and new pacemakers in 17.4% versus 2.3%, with replacement versus medical therapy. Sources: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. Portrait source ↗ interventional cardiologist Susheel K. Kodali NYU Langone → Interventional cardiologist; System Director of Interventional Cardiology and Co-Director of Structural Heart Program Interventional cardiologist; System Director of Interventional Cardiology and Co-Director of Structural Heart Program · New York, United States. Read the clinical or research source ↗","related_documents":[{"id":"heart-surgery","title":"Heart surgery abroad: treatments, clinics and costs","kind":"home","url":"https://hub.bookimed.com/heart-surgery/","json_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/heart-surgery.json"},{"id":"surgeons","title":"Find cardiac surgeons and heart specialists by procedure","kind":"surgeons","url":"https://hub.bookimed.com/heart-surgery/surgeons/","json_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/surgeons.json"},{"id":"surgeon-rankings","title":"Heart surgeon rankings by reported experience, method and results","kind":"guide","url":"https://hub.bookimed.com/heart-surgery/surgeon-rankings/","json_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/surgeon-rankings.json"},{"id":"tricuspid-valve-disease","title":"Tricuspid valve disease: repair, replacement and catheter options","kind":"guide","url":"https://hub.bookimed.com/heart-surgery/tricuspid-valve-disease/","json_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/tricuspid-valve-disease.json"},{"id":"clinic-nyu-langone","title":"NYU Langone: heart surgery expertise","kind":"clinic-profile","url":"https://hub.bookimed.com/heart-surgery/clinic-nyu-langone/","json_url":"https://hub.bookimed.com/wp-content/uploads/heart-surgery-hub-20261007/pages/clinic-nyu-langone.json"}],"entity":{"id":"susheel-kodali","name":"Susheel K. Kodali","programme_id":"nyu-langone","role":"Interventional cardiologist; System Director of Interventional Cardiology and Co-Director of Structural Heart Program","procedure_relevance":["Catheter-based tricuspid, mitral and aortic therapies; particularly evaluation for transcatheter tricuspid treatment."],"source_ids":["SP11","SP12","SP20"],"official_url":"https://nyulangone.org/doctors/1659455335/susheel-k-kodali","clinical_role_type":"interventional-cardiologist","topic_slugs":["tricuspid-valve-disease"],"method_tags":["tricuspid-transcatheter-repair","tricuspid-transcatheter-replacement"],"profile":{"intro":"Susheel Kodali is an NYU Langone interventional cardiologist specialising in transcatheter valve therapies. His trial work is relevant to severe tricuspid leakage, where symptom benefit must be weighed against bleeding and pacemaker risks.","clinical_focus":[{"label":"Current NYU appointment","text":"NYU announced his move in August 2026; earlier Columbia affiliations belong to his research history.","source_ids":["SP11","SP12"]},{"label":"Patient-centred benefit","text":"The 400-patient TRISCEND II trial favoured replacement plus medical therapy at one year, principally through symptoms and quality of life.","source_ids":["SP20"]},{"label":"Material trade-offs","text":"Severe bleeding occurred in 15.4% versus 5.3%, and new pacemakers in 17.4% versus 2.3%, with replacement versus medical therapy.","source_ids":["SP20"]}],"evidence":[{"title":"Replacement: symptoms, function and procedure risks","summary":"In the 400-patient TRISCEND II randomized trial, replacement plus medical therapy improved the one-year composite outcome, mainly through symptoms and quality of life. Severe bleeding and new pacemakers were more frequent with replacement.","source_ids":["SP20"],"limitations":"Device-specific, selected-patient, multicentre evidence. It does not establish a survival advantage or Kodali-specific success rate, and is not a comparison of replacement with tricuspid repair or surgery."}],"consultation_questions":[],"current_role_note":"Interventional cardiologist; System Director of Interventional Cardiology and Co-Director of Structural Heart Program · New York, United States.","key_takeaways":[{"label":"Current NYU appointment","text":"NYU announced his move in August 2026; earlier Columbia affiliations belong to his research history.","sources":["SP11","SP12"]},{"label":"Patient-centred benefit","text":"The 400-patient TRISCEND II trial favoured replacement plus medical therapy at one year, principally through symptoms and quality of life.","sources":["SP20"]},{"label":"Material trade-offs","text":"Severe bleeding occurred in 15.4% versus 5.3%, and new pacemakers in 17.4% versus 2.3%, with replacement versus medical therapy.","sources":["SP20"]}],"benefits":[{"text":"For the selected patients studied in TRISCEND II, catheter tricuspid replacement improved symptoms and quality of life over medical therapy alone at one year.","sources":["SP20"]}],"limitations":[{"text":"The trial evaluated one replacement system in selected patients. It does not establish a survival advantage or compare replacement with tricuspid repair or open surgery; its outcomes are not Kodali’s personal rate.","sources":["SP11","SP12","SP20"]}],"patient_sections":[{"id":"benefit-balance","title":"Benefits and limitations","paragraphs":[],"items":[],"sources":[],"kind":"benefit-balance","links":[],"table":null},{"id":"research","title":"Procedure-specific research","paragraphs":[],"items":[],"sources":[],"kind":"doctor-evidence","links":[],"table":null},{"id":"team","title":"Clinical programme","paragraphs":[],"items":[],"sources":[],"kind":"doctor-clinic","links":[],"table":null}]},"bookimed_route":null,"portrait":{"url":"https://hub.bookimed.com/wp-content/uploads/2026/10/susheel-kodali-300x300.jpg","source_page":"https://nyulangone.org/doctors/1659455335/susheel-k-kodali","width":2176,"height":2177,"alt":"Susheel K. Kodali, MD"},"topics":["tricuspid"],"headline":"transcatheter tricuspid valve treatment","profile_slug":"doctor-susheel-kodali","discipline":"interventional cardiologist"},"sources":{"depth-swistel":{"title":"NYU Langone · Daniel Swistel","url":"https://nyulangone.org/doctors/1083603690/daniel-g-swistel","publisher":"Official hospital / clinical programme","read_at":"2026-10-08","label":"NYU Langone · Daniel Swistel"},"depth-nyu-hcm":{"title":"NYU Langone · HCM programme","url":"https://nyulangone.org/care-services/hypertrophic-cardiomyopathy-program","publisher":"Official hospital / clinical programme","read_at":"2026-10-08","label":"NYU Langone · HCM programme"},"depth-rpr77":{"title":"Resect–plicate–release · 77-patient study (2015)","url":"https://pubmed.ncbi.nlm.nih.gov/26272699/","publisher":"Journal of the American Society of Echocardiography / PubMed","read_at":"2026-10-08","label":"Resect–plicate–release · 77-patient study (2015)","retrieval":"Europe PMC full indexed abstract"},"SP11":{"title":"Susheel K. Kodali, MD — physician profile","publisher":"NYU Langone Health","url":"https://nyulangone.org/doctors/1659455335/susheel-k-kodali","read_at":"2026-10-08","source_kind":"official-institution","local_body":"/Users/eugen/Projects/frankenstein-agentic-framework/outputs/heart-surgery-hub-20261007/review/provider-depth/specialties/sources/kodali-profile.txt","supports":"Adult interventional cardiologist, current NYU role, aortic/mitral/tricuspid transcatheter therapies and trial leadership.","limitations":"He is not a cardiac surgeon. Earlier Columbia trial affiliations are historical."},"SP12":{"title":"NYU welcomes Susheel Kodali to lead interventional cardiology","publisher":"NYU Langone Health","url":"https://nyulangone.org/news/nyu-langone-names-sunil-rao-md-director-leon-h-charney-division-cardiology-and-welcomes-susheel-kodali-md-lead-interventional-cardiology","read_at":"2026-10-08","source_kind":"official-institution","local_body":"/Users/eugen/Projects/frankenstein-agentic-framework/outputs/heart-surgery-hub-20261007/review/provider-depth/specialties/sources/kodali-move.txt","supports":"NYU appointment and move from Columbia; director of interventional cardiology and Manhattan catheterization laboratory.","limitations":"","published_at":"2026-08-27"},"SP20":{"title":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","publisher":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39475399/","read_at":"2026-10-08","published_at":"2024-10-30","doi":"10.1056/nejmoa2401918","pmid":"39475399","source_kind":"primary-research-abstract","local_body":"/Users/eugen/Projects/frankenstein-agentic-framework/outputs/heart-surgery-hub-20261007/review/provider-depth/specialties/sources/pmid-39475399.json","supports":"TRISCEND II, 400 randomized severe symptomatic TR patients; replacement plus medical therapy improved composite at one year, principally symptoms and quality of life.","limitations":"Multicentre device-specific trial, not individual/NYU performance; higher severe bleeding and new pacemaker rates; no claim of established survival benefit. Funded by Edwards Lifesciences."},"pc-nyu-programme":{"title":"NYU HCM programme","url":"https://nyulangone.org/care-services/hypertrophic-cardiomyopathy-program","kind":"official hospital page","checked":"2026-10-08","accessed":"2026-10-08"},"pc-nyu-swistel":{"title":"Current official Swistel profile","url":"https://nyulangone.org/doctors/1083603690/daniel-g-swistel","kind":"official hospital page","checked":"2026-10-08","accessed":"2026-10-08"},"pc-nyu-robotic":{"title":"NYU first robotic myectomy clinical case","url":"https://physicianfocus.nyulangone.org/nyu-langones-first-robotic-septal-myectomy-for-obstructive-hcm/","kind":"official hospital page","checked":"2026-10-08","accessed":"2026-10-08"},"pc-rpr77":{"title":"Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy.","url":"https://pubmed.ncbi.nlm.nih.gov/26272699/","kind":"primary peer-reviewed study; indexed abstract","checked":"2026-10-08","accessed":"2026-10-08"},"volume-nyu-programme-cumulative":{"id":"volume-nyu-programme-cumulative","title":"NYU HCM programme","url":"https://nyulangone.org/care-services/hypertrophic-cardiomyopathy-program","publisher":"Institution / clinical programme","published":null,"read_at":"2026-10-08","source_type":"Reported clinical activity; scope shown with figure"}}}